donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

GBT Global Blood Therapeutics

66.750
+0.180+0.27%
Close 08/12 16:00 ET
66.720
-0.03-0.04%
Post Mkt Price 08/12 16:06 ET
High
66.810
Open
66.670
Turnover
384.06M
Low
66.590
Pre Close
66.570
Volume
5.76M
Market Cap
4.50B
P/E(TTM)
Loss
52wk High
73.020
Shares
67.46M
P/E(Static)
Loss
52wk Low
21.650
Float Cap
3.51B
Bid/Ask %
-50.00%
Historical High
87.540
Shs Float
52.61M
Volume Ratio
0.40
Historical Low
12.240
Dividend TTM
--
Div Yield TTM
250
P/B
38.06
Dividend LFY
--
Div Yield LFY
374.53%
Turnover Ratio
10.94%
Amplitude
0.33%
Avg Price
66.720
Lot Size
1
Float Cap
3.51B
Bid/Ask %
-50.00%
Historical High
87.540
Shs Float
52.61M
Volume Ratio
0.40
Historical Low
12.240
Dividend TTM
--
P/B
38.06
Dividend LFY
--
Turnover Ratio
10.94%
Amplitude
0.33%
Avg Price
66.720
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
CEO: Love M.D., Ted W.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...